These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 36808168)

  • 1. How do patients feel during the first 72 h after initiating long-acting injectable buprenorphine? An embodied qualitative analysis.
    Neale J; Parkin S; Strang J
    Addiction; 2023 Jul; 118(7):1329-1339. PubMed ID: 36808168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients' goals when initiating long-acting injectable buprenorphine treatment for opioid use disorder: findings from a longitudinal qualitative study.
    Neale J; Parkin S; Strang J
    Subst Abuse Treat Prev Policy; 2023 Jun; 18(1):37. PubMed ID: 37349776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'Matters-of-concern' associated with discontinuation of long-acting injectable buprenorphine: Findings from a longitudinal qualitative study.
    Parkin S; Neale J; Strang J
    Int J Drug Policy; 2024 Jul; 129():104470. PubMed ID: 38843737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conceptualising retention in treatment with long-acting injectable buprenorphine (for opioid use disorder) as a journey: Findings from a longitudinal qualitative study.
    Parkin S; Neale J; Strang J
    Int J Drug Policy; 2023 Dec; 122():104221. PubMed ID: 37865052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare staff's perspectives on long-acting injectable buprenorphine treatment: a qualitative interview study.
    Nordgren J; Monwell B; Johnson B; Gunnarsson NV; Capusan AJ
    Addict Sci Clin Pract; 2024 Apr; 19(1):25. PubMed ID: 38581022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Acting Injectable Buprenorphine for Opioid Use Disorder: A Qualitative Analysis of Patients' Interpersonal Relationships during the First Year of Treatment.
    Neale J; Strang J
    Subst Use Misuse; 2024; 59(14):2064-2072. PubMed ID: 39165015
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-acting injectable depot buprenorphine from a harm reduction perspective in patients with ongoing substance use and multiple psychiatric comorbidities: a qualitative interview study.
    Johnson B; Monwell B; Capusan AJ
    Harm Reduct J; 2024 Mar; 21(1):68. PubMed ID: 38528531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia.
    Barnett A; Savic M; Lintzeris N; Bathish R; Arunogiri S; Dunlop AJ; Haber P; Graham R; Hayes V; Lubman DI
    Drug Alcohol Depend; 2021 Oct; 227():108959. PubMed ID: 34450472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence.
    Godersky ME; Saxon AJ; Merrill JO; Samet JH; Simoni JM; Tsui JI
    Addict Sci Clin Pract; 2019 Mar; 14(1):11. PubMed ID: 30867068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct induction onto high-dose long-acting injectable buprenorphine: A case series.
    Naren T; Cook J; MacCartney P
    Australas Psychiatry; 2024 Jun; 32(3):238-241. PubMed ID: 38444394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-Prescribed Substance Use during the First Month of Treatment by People Receiving Depot Buprenorphine for Opioid Use Disorder.
    Parkin S; Neale J; Strang J
    Subst Use Misuse; 2023; 58(13):1696-1706. PubMed ID: 37571999
    [No Abstract]   [Full Text] [Related]  

  • 13. Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.
    Yarborough BJ; Stumbo SP; McCarty D; Mertens J; Weisner C; Green CA
    Drug Alcohol Depend; 2016 Mar; 160():112-8. PubMed ID: 26796596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine.
    Silverstein SM; Daniulaityte R; Miller SC; Martins SS; Carlson RG
    Drug Alcohol Depend; 2020 May; 210():107958. PubMed ID: 32203863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "The Doctor Says You Cannot Have [Buprenorphine]" Autonomy and Use of Prescribed or Non-Prescribed Buprenorphine.
    Hayes BT; Jakubowski A; Fitzsimmons C; Garcia B; Ramirez F; Fox AD
    Subst Use Misuse; 2021; 56(8):1137-1143. PubMed ID: 33939937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 'I just thought that was the best thing for me to do at this point': Exploring patient experiences with depot buprenorphine and their motivations to discontinue.
    Clay S; Treloar C; Degenhardt L; Grebely J; Christmass M; Gough C; Hayllar J; McDonough M; Henderson C; Crawford S; Farrell M; Marshall A
    Int J Drug Policy; 2023 May; 115():104002. PubMed ID: 37003194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the effectiveness of a regional nurse practitioner led, long-acting injectable buprenorphine-based model of care for opioid use disorder.
    Strike T; D'Angelo-Kemp D; Searby A
    Int J Ment Health Nurs; 2023 Aug; 32(4):1129-1137. PubMed ID: 37070663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inpatient initiation of long-acting injectable buprenorphine at a community hospital: A retrospective case series.
    O'Conor C; Farhi S; Cowan E; Fitzgerald R
    J Addict Dis; 2024 Sep; ():1-7. PubMed ID: 39219151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dynamics of more-than-human care in depot buprenorphine treatment: A new materialist analysis of Australian patients' experiences.
    Barnett A; Pienaar K; Lubman DI; Arunogiri S; Phan V; Hayes V; Lintzeris N; Savic M
    Int J Drug Policy; 2024 May; 127():104399. PubMed ID: 38636315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine Treatment for Opioid Use Disorder: An Overview.
    Shulman M; Wai JM; Nunes EV
    CNS Drugs; 2019 Jun; 33(6):567-580. PubMed ID: 31062259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.